Clinical Trials Logo

Clinical Trial Summary

This is a FIH, single center, open label, non-randomized, single-arm, Phase I clinical trial to evaluate the safety and tolerability of CD5 CAR T cells in subjects with relapsed or refractory T-cell acute lymphoblastic leukemia. At least 18 subjects will be enrolled. After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m^2/day and cyclophosphamide at 250 mg/m^2/day; for prior-SCT donor-derived CAR T-cell infusion) or intensified lymphodepletion (fludarabine at 30 mg/m^2/day and cyclophosphamide at 30 mg/kg/day; for new donor-derived CAR T-cell infusion) will be administrated for 3 days. Then this study will be using BOIN1/2 approach from starting dose 1: 1×10^6 (±30%) to dose 2: 2×10^6 (±30%). If the manufactured cells were not sufficient to meet the preassigned standard dose criteria, patients are given infusion at a low dose of 5×10^5 (±30%) /kg.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Leukemia
  • Leukemia, Lymphoid
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  • T-Cell Acute Lymphoblastic Leukemia

NCT number NCT05032599
Study type Interventional
Source Beijing Boren Hospital
Contact Jing Pan, Master
Phone +8618911067969
Email [email protected]
Status Recruiting
Phase Phase 1
Start date September 1, 2021
Completion date September 1, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04972942 - Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma Phase 2
Recruiting NCT04033302 - Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies Phase 1/Phase 2
Completed NCT01950286 - Hyper-CVAD Treatment of Adult T-cell Acute Lymphoblastic Leukemia in Sweden. N/A
Completed NCT02518113 - A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL Phase 1/Phase 2
Not yet recruiting NCT04984356 - A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL Phase 1/Phase 2
Recruiting NCT03081910 - Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen Phase 1
Not yet recruiting NCT04860817 - A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL Early Phase 1
Recruiting NCT04594135 - Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies Phase 1
Recruiting NCT04934774 - Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances Phase 1
Recruiting NCT03690011 - Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells Phase 1